Stock 688621 BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Equities

688621

CNE100005139

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
57.69 CNY +1.51% Intraday chart for Beijing Sun-Novo Pharmaceutical Research Co., Ltd. -2.88% -17.29%
Apr. 25 Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 26 Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Beijing Sun Novo Pharmaceutical Research Co Ltd is a China-based company that provides research and development outsourcing services for pharmaceutical companies. The Company's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The Company mainly conducts its businesses in the domestic market.

Number of employees: 1,126

Sales per Business

CNY in Million2021Weight2022Weight Delta
Pharmaceutical Research Services
65.3 %
279 56.4 % 442 65.3 % +58.66%
Clinical Trials and Bioanalytical Services
34.7 %
214 43.4 % 234 34.7 % +9.40%
Other
0.0 %
1 0.2 % 0 0.0 % -73.16%

Sales per region

CNY in Million2021Weight2022Weight Delta
China
100.0 %
494 100.0 % 677 100.0 % +37.06%

Managers

Managers TitleAgeSince
Yu Jing Liu CEO
 Chief Executive Officer 42 09-02-28
Ling Yang Zhao DFI
 Director of Finance/CFO 36 20-03-20
Ming Juan Wang CTO
 Chief Tech/Sci/R&D Officer 48 -
Guang Tao Hao PRN
 Corporate Officer/Principal 44 20-03-20

Members of the board

Members of the board TitleAgeSince
Qian Li CHM
 Chairman 43 09-03-08
Qiao Chen BRD
 Director/Board Member 44 20-03-20
Zhuang Kun He BRD
 Director/Board Member 52 20-03-20
Wen Ran Li BRD
 Director/Board Member 41 20-03-20
Ling Yang Zhao DFI
 Director of Finance/CFO 36 20-03-20
Yu Jing Liu CEO
 Chief Executive Officer 42 09-02-28
Ying Zhang BRD
 Director/Board Member 38 20-03-20
Dan Dan Wang CHM
 Chairman 42 09-12-31
Jin Feng Zhang BRD
 Director/Board Member 40 17-08-31
Hui Ting Zhu BRD
 Director/Board Member 41 22-11-08

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 112,000,000 57,567,390 ( 51.40 %) 0 51.40 %

Shareholders

NameEquities%Valuation
Fullgoal Fund Management Co., Ltd.
13.50 %
10,951,999 13.50 % 94 M ¥
Yu Jing Liu
5.611 %
4,550,386 5.611 % 39 M ¥
Basic Pension Insurance Fund 16022 Portfolio
4.510 %
3,657,454 4.510 % 31 M ¥
Rongtong Fund Management Co., Ltd.
4.251 %
3,447,930 4.251 % 30 M ¥
Yan Shao
4.143 %
3,360,000 4.143 % 29 M ¥
Zhong Ou Asset Management Co., Ltd
3.198 %
2,593,379 3.198 % 22 M ¥
Xin Quan Tuo
3.112 %
2,524,000 3.112 % 22 M ¥
GF Xinde Investment Management Co. Ltd.
2.775 %
2,250,896 2.775 % 19 M ¥
Essence Fund Co., Ltd.
2.745 %
2,226,514 2.745 % 19 M ¥
Wuhan State Owned Assets Sup. & Adm. Commssion
2.702 %
2,191,007 2.702 % 19 M ¥
NameEquities%Valuation
Qian Li
100.00 %
30,897,300 100.00 % 266 M ¥

Company contact information

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

1st Floor, Building 7 79 Shuangying West Road

102200, Beijing

+

http://www.sun-novo.com
address Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(688621)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Ratings for Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
57.69
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD. Stock Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
-17.29% 878M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 688621 Stock
  4. Company Beijing Sun-Novo Pharmaceutical Research Co., Ltd.